FDA clears Zilbrysq injector as UCB stock costs EUR 217.45

Published on 10/21/2026 at 10:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB targets first-quarter 2027 availability for its device. UCB stock costs EUR 217.45 on October 21, 2026, below its EUR 289.50 high.

Growth and regulatory milestones

UCB secured FDA approval for a Zilbrysq auto-injector on October 16, 2026, with 99.80 percent full-dose delivery.
First-half 2026 revenue reached EUR 4.27 billion, up 23.00 percent year over year.
UCB stock traded at EUR 217.45 at 10:35 a.m. CEST at Lang & Schwarz on October 21, 2026.

Isometrische 3D-Illustration einer Wertschöpfungskette von Labor über Produktion bis zum Krankenhaus — UCB S.A. mit ISIN BE0003739530 dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) stock was trading at EUR 217.45 at Lang & Schwarz on October 21, 2026, while the Belgian drugmaker's recent FDA approval added a concrete product milestone. On October 16, 2026, the U.S. regulator approved a self-injectable form of Zilbrysq for adults with generalized myasthenia gravis, with commercial availability planned for the first quarter of 2027, according to Ideal Investor.

FDA approval adds a practical milestone

The approval changes how patients can administer the existing treatment. The auto-injector delivered a full dose in 99.80 percent of 449 returned devices, while 90.00 percent of 100 participants completed their first injection without prior training, the same report said.

Zilbrysq is part of UCB's neurology and immunology portfolio. The company is also developing further therapies in myasthenia gravis, including Rystiggo, giving the regulatory decision a direct connection to its commercial strategy.

What supports the growth case?

UCB's first-half 2026 figures show the scale behind that strategy. Revenue reached EUR 4.27 billion, up 23.00 percent from the first half of 2025, while net income rose to EUR 1.11 billion from EUR 476.00 million, according to Ideal Investor. The reported profit increase was accompanied by adjusted EBITDA of EUR 1.69 billion and an adjusted EBITDA margin of 40.70 percent.

The product mix is concentrated around established growth drivers. BIMZELX generated EUR 1.52 billion in first-half 2026 sales, while FINTEPLA contributed EUR 239.00 million and RYSTIGGO EUR 192.00 million. UCB's investor materials also place BIMZELX peak sales guidance above EUR 7.00 billion.

Analyst target moves lower

On October 20, 2026, Oddo BHF kept an Outperform rating but cut its UCB price target from EUR 293.00 to EUR 260.00, according to Zonebourse. The target change places the analyst view below the broader consensus target of EUR 283.26 cited on the same page.

Next reporting date

The next dated company event is the publication of full-year 2026 results on February 25, 2027, according to the investor calendar shown by Zonebourse.

Stock remains below yearly high

UCB stock's EUR 217.45 intraday quote stands below the EUR 289.50 52-week high and above the EUR 197.45 low. The primary listing is Euronext Brussels, where the finance quote showed EUR 217.90 at 10:23 a.m. CEST on October 21, 2026.

At Lang & Schwarz, UCB stock was trading at EUR 217.45 on October 21, 2026 at 10:35 a.m. CEST.